Coherus Oncology (CHRS) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Protara Therapeutics (TARA) over the past year, losing 41.2% versus a loss of 50.9%. Over five years, TARA leads with a -59.7% price change compared with -93.7% for CHRS. Coherus Oncology is the larger company by market cap ($165.3 million vs $162.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | TARA |
|---|---|---|
| Share price | $1.07 | $2.76 |
| Market cap | $165.32M | $162.81M |
| 1-day change | 0.00% | +3.96% |
| YTD return | -24.65% | -48.31% |
| 1-year return | -41.21% | -50.89% |
| 5-year return | -93.71% | -59.72% |
| EPS (TTM) | $-1.27 | $-1.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $7.82 |
| 52-week low | $0.974 | $2.51 |
| Distance from 52-week high | -59.10% | -64.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +624.30% | +833.21% |
| Average volume | 1.16M | 814.80K |
| Shares outstanding | 154.50M | 59.10M |
| Employees | 144 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CHRS vs TARA FAQ
Which is bigger, Coherus Oncology or Protara Therapeutics?
Coherus Oncology (CHRS) is larger, with a market capitalization of $165.32M compared with $162.81M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, CHRS or TARA?
CHRS returned -41.21% over the past 12 months, compared with -50.89% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.